WCO-IOF: Methotrexate may reduce BMD loss in patients with rheumatoid arthritis .
Osteoporosis in patients with rheumatoid arthritis: methotrexate compared with leflunomide treatment alone
40 patients with active rheumatoid arthritis were randomized to receive methotrexate or leflunomide to compare treatment effects on bone loss over a 12 month period. Upon analysis, bone mineral density (BMD) loss in the methotrexate group was significantly reduced at the femoral neck, total hip, and L2-4 spine compared to the leflunomide group. BMD loss at the hand was similar between the two groups. Subgroup analysis indicated an increase in BMD in patients treated with bisphosphonates, while a decrease in BMD was observed in those that did not undergo antirersorptive therapy.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!
0 of 4 monthly FREE articles unlocked
